

Press Release
25 May 2023 13:00:00 CEST



Newbury to present at Redeye Growth Day 2023

On June 1st at 10:00 CEO, Lars Minor will discuss the latest developments in Newbury Pharmaceuticals at Redeye Growth Day 2023.

The In Focus interview is live broadcasted from Scandic Haymarket in Stockholm and can be followed at <https://www.redeye.se/events/871323/redeye-growth-day>

To get a preparatory introduction to Newbury Pharmaceuticals, please watch the Newbury Investor site for more information and recordings of company presentations <https://www.newburypharma.com/investors/>

A company presentation is also available at the Redeye event site with the possibility of posting questions <https://www.redeye.se/video/company-prerecorded-presentation/911468/newbury-pharmaceuticals-3>

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury to present at Redeye Growth Day 2023](#)